Stock listing
Shenzhen:002399 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (海普瑞) 股价
Home listing (Shenzhen) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Follow Shenzhen Hepalink Pharmaceutical Group Co., Ltd. into a list and get an email when it puts out news.
Share price · SZSE:002399
¥8.67 CNY -0.39 (-4.3%)
Close on Nov 20, 2026
- Day range
- ¥8.65 – ¥8.93 CNYNov 20, 2026
- Volume
- 3.72M sharesNov 20, 2026
- Market cap
- ¥10.81B CNYAt the close on Nov 20, 2026 · price × 1.25B shares outstanding
- 52-week range
- ¥8.50 – ¥12.64 CNYLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ¥41.93M CNYMedian day 3.57M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Shenzhen:002399 · Home | ¥8.67 CNY | -0.39 (-4.3%) | 3,718,580 | ¥8.92 | ¥8.93 | ¥8.65 | ¥9.06 | Close on Nov 20, 2026 |
| HKEX:9989 | $3.79 HKD | -0.125 (-3.2%) | 958,000 | $3.845 | $3.955 | $3.71 | $3.915 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · SZSE:002399 · CNY, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ¥8.67 | -0.39 | -4.3% | ¥8.92 | ¥8.93 | ¥8.65 | 3,718,580 | |
| ¥9.06 | -0.02 | -0.2% | ¥9.06 | ¥9.22 | ¥9.01 | 1,981,676 | |
| ¥9.08 | -0.04 | -0.4% | ¥9.02 | ¥9.18 | ¥9.02 | 1,782,661 | |
| ¥9.12 | +0.02 | +0.2% | ¥9.11 | ¥9.17 | ¥9.03 | 1,950,236 | |
| ¥9.10 | -0.15 | -1.6% | ¥9.26 | ¥9.26 | ¥9.05 | 2,832,968 | |
| ¥9.25 | 0.00 | 0.0% | ¥9.25 | ¥9.32 | ¥9.17 | 2,112,520 | |
| ¥9.25 | -0.06 | -0.6% | ¥9.29 | ¥9.36 | ¥9.20 | 2,011,020 | |
| ¥9.31 | -0.01 | -0.1% | ¥9.42 | ¥9.42 | ¥9.30 | 2,304,540 | |
| ¥9.32 | -0.12 | -1.3% | ¥9.50 | ¥9.51 | ¥9.31 | 2,856,018 | |
| ¥9.44 | -0.16 | -1.7% | ¥9.43 | ¥9.58 | ¥9.38 | 2,651,353 | |
| ¥9.60 | +0.17 | +1.8% | ¥9.40 | ¥9.62 | ¥9.38 | 3,708,854 | |
| ¥9.43 | +0.12 | +1.3% | ¥9.37 | ¥9.45 | ¥9.17 | 4,291,900 | |
| ¥9.31 | -0.01 | -0.1% | ¥9.24 | ¥9.42 | ¥9.21 | 3,070,200 | |
| ¥9.32 | +0.10 | +1.1% | ¥9.22 | ¥9.35 | ¥9.10 | 3,862,100 | |
| ¥9.22 | +0.14 | +1.5% | ¥9.27 | ¥9.43 | ¥8.97 | 5,365,973 | |
| ¥9.08 | -0.13 | -1.4% | ¥9.18 | ¥9.24 | ¥9.07 | 2,004,000 | |
| ¥9.21 | +0.15 | +1.7% | ¥9.06 | ¥9.30 | ¥9.05 | 3,028,400 | |
| ¥9.06 | -0.29 | -3.1% | ¥9.39 | ¥9.42 | ¥9.06 | 2,845,800 | |
| ¥9.35 | +0.08 | +0.9% | ¥9.20 | ¥9.42 | ¥9.18 | 3,079,900 | |
| ¥9.27 | +0.13 | +1.4% | ¥9.11 | ¥9.27 | ¥8.95 | 3,102,200 | |
| ¥9.14 | -0.19 | -2.0% | ¥9.33 | ¥9.36 | ¥9.14 | 2,519,200 | |
| ¥9.33 | -0.07 | -0.7% | ¥9.41 | ¥9.49 | ¥9.31 | 1,950,500 | |
| ¥9.40 | +0.07 | +0.8% | ¥9.31 | ¥9.41 | ¥9.28 | 2,064,860 | |
| ¥9.33 | +0.01 | +0.1% | ¥9.30 | ¥9.45 | ¥9.23 | 2,245,400 | |
| ¥9.32 | -0.08 | -0.9% | ¥9.49 | ¥9.66 | ¥9.23 | 3,601,520 | |
| ¥9.40 | -0.07 | -0.7% | ¥9.35 | ¥9.49 | ¥9.31 | 2,592,000 | |
| ¥9.47 | -0.15 | -1.6% | ¥9.59 | ¥9.61 | ¥9.45 | 3,096,540 | |
| ¥9.62 | -0.11 | -1.1% | ¥9.65 | ¥9.68 | ¥9.45 | 4,053,160 | |
| ¥9.73 | -0.16 | -1.6% | ¥9.88 | ¥9.94 | ¥9.69 | 3,749,140 | |
| ¥9.89 | +0.14 | +1.4% | ¥9.72 | ¥9.90 | ¥9.58 | 3,759,000 | |
| ¥9.75 | -0.10 | -1.0% | ¥9.99 | ¥10.00 | ¥9.70 | 4,326,820 | |
| ¥9.85 | +0.24 | +2.5% | ¥9.61 | ¥9.92 | ¥9.56 | 4,148,623 | |
| ¥9.61 | -0.05 | -0.5% | ¥9.65 | ¥9.77 | ¥9.56 | 2,899,500 | |
| ¥9.66 | +0.08 | +0.8% | ¥9.63 | ¥9.70 | ¥9.57 | 3,231,383 | |
| ¥9.58 | -0.15 | -1.5% | ¥9.73 | ¥9.80 | ¥9.50 | 3,541,620 | |
| ¥9.73 | -0.02 | -0.2% | ¥9.73 | ¥9.88 | ¥9.71 | 3,278,200 | |
| ¥9.75 | -0.05 | -0.5% | ¥9.79 | ¥9.86 | ¥9.63 | 3,896,500 | |
| ¥9.80 | +0.45 | +4.8% | ¥9.37 | ¥9.81 | ¥9.37 | 6,347,909 | |
| ¥9.35 | -0.13 | -1.4% | ¥9.48 | ¥9.69 | ¥9.35 | 6,234,608 | |
| ¥9.48 | +0.06 | +0.6% | ¥9.43 | ¥9.50 | ¥9.39 | 1,862,900 | |
| ¥9.42 | +0.04 | +0.4% | ¥9.40 | ¥9.43 | ¥9.29 | 2,438,280 | |
| ¥9.38 | -0.23 | -2.4% | ¥9.61 | ¥9.63 | ¥9.38 | 2,121,000 | |
| ¥9.61 | +0.13 | +1.4% | ¥9.47 | ¥9.65 | ¥9.44 | 2,512,524 | |
| ¥9.48 | -0.34 | -3.5% | ¥9.75 | ¥9.81 | ¥9.40 | 4,419,170 | |
| ¥9.82 | -0.17 | -1.7% | ¥9.94 | ¥9.95 | ¥9.80 | 3,893,700 | |
| ¥9.99 | -0.04 | -0.4% | ¥9.98 | ¥10.02 | ¥9.90 | 3,358,500 | |
| ¥10.03 | +0.19 | +1.9% | ¥9.84 | ¥10.04 | ¥9.79 | 4,734,148 | |
| ¥9.84 | +0.01 | +0.1% | ¥9.79 | ¥9.86 | ¥9.74 | 4,028,348 | |
| ¥9.83 | -0.06 | -0.6% | ¥9.92 | ¥9.99 | ¥9.81 | 4,175,920 | |
| ¥9.89 | -0.08 | -0.8% | ¥9.98 | ¥10.09 | ¥9.89 | 4,148,042 | |
| ¥9.97 | -0.11 | -1.1% | ¥9.96 | ¥10.08 | ¥9.91 | 4,488,328 | |
| ¥10.08 | +0.04 | +0.4% | ¥10.01 | ¥10.16 | ¥9.97 | 5,827,285 | |
| ¥10.04 | -0.41 | -3.9% | ¥10.18 | ¥10.22 | ¥9.95 | 7,688,460 | |
| ¥10.45 | -0.15 | -1.4% | ¥10.51 | ¥10.59 | ¥10.42 | 5,347,000 | |
| ¥10.60 | +0.20 | +1.9% | ¥10.38 | ¥10.60 | ¥10.31 | 6,685,978 | |
| ¥10.40 | +0.09 | +0.9% | ¥10.33 | ¥10.78 | ¥10.33 | 8,545,934 | |
| ¥10.31 | +0.31 | +3.1% | ¥10.03 | ¥10.39 | ¥9.91 | 9,611,128 | |
| ¥10.00 | -0.47 | -4.5% | ¥10.40 | ¥10.46 | ¥9.98 | 12,512,234 | |
| ¥10.47 | -0.81 | -7.2% | ¥11.51 | ¥11.57 | ¥10.45 | 22,933,199 | |
| ¥11.28 | +1.03 | +10.0% | ¥11.02 | ¥11.28 | ¥11.02 | 8,784,664 |
Splits
2 splits since 2011 · SZSE:002399 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 8-for-5 | Split | |
| 2-for-1 | Split |
- Ticker
- Shenzhen:002399
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Shenzhen
- Currency
- CNY
Latest news
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 11 in all · newest May 6, 2021 · oldest 2020
Where Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Shenzhen:002399 海普瑞 · Home listing · This page | Shenzhen | China | CNY |
| HKEX:9989 海普瑞 | HKEX | Hong Kong | HKD |
Valuation
P/E 57.0× against a median of 13.6×: 7th lowest of 9 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ¥6.57B CNY
- P/E
- 57.0×
- EV/sales
- 1.3×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- 34.0%
- Operating margin
- 11.6%
- Net margin
- 3.7%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A · SZSE:002399 | US$1.62B | US$986.2M | 57.0× | 1.3× | n/a | 0.9× | 3.7% | 0.0× | n/a |
| Ultragenyx Pharmaceutical Inc. · NASDAQ:RARE | US$1.68B | US$2.60B | n/a | 3.6× | n/a | n/a | −71.8% | n/a | 1.35 |
| Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN | US$1.67B | US$1.85B | 3.7× | 1.4× | n/a | n/a | 32.9% | n/a | 0.67 |
| Caplin Point Laboratories Limited · NSE:CAPLIPOINT | US$1.66B | US$1.56B | 23.2× | 6.3× | 18.1× | 4.3× | 29.1% | 0.0× | n/a |
| AstraZeneca Pharma India Limited · NSE:ASTRAZEN | US$1.66B | US$1.60B | 86.8× | 5.7× | 59.3× | 17.5× | 6.8% | 0.0× | n/a |
| Hugel, Inc. · KRX:145020 | US$1.66B | US$1.21B | 14.1× | 3.4× | 7.1× | 2.1× | 32.9% | 0.0× | n/a |
| Agios Pharmaceuticals, Inc. · NASDAQ:AGIO | US$1.65B | US$1.05B | n/a | 7.4× | n/a | 1.7× | −264.8% | 0.0× | 1.10 |
| Faes Farma, S.A. · BME:FAE | US$1.65B | US$1.93B | 11.0× | 1.7× | 5.8× | 1.9× | 13.1% | 0.5× | n/a |
| Consun Pharmaceutical Group Ltd. · HKEX:1681 | US$1.64B | US$1.06B | 10.1× | 2.1× | 5.6× | 2.3× | 31.6% | 0.1× | n/a |
| BrightGene Bio-Medical Technology Co. Ltd. Class A · SSE:688166 | US$1.63B | US$1.68B | 106× | 8.3× | n/a | 3.5× | 7.6% | 0.5× | n/a |
| NATCO Pharma Limited · NSE:NATCOPHARM | US$1.62B | US$1.62B | 13.1× | 4.3× | 14.2× | 1.6× | 32.8% | 0.0× | n/a |
| Median of the others | US$1.65B | US$1.61B | 13.6× | 3.9× | 10.7× | 2.2× | 21.1% | 0.0× | 1.10 |
Forecasts
Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 CNY · Analysts' mean
- EPS, year to Dec 2026
- 0.50 · 1 analyst
- Revenue, year to Dec 2026
- 5.1B · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Juan Chen | Chief Financial Officer |
| Li Li | President and Chairman |
| Fengqi Qian | Secretary to the Board, Joint Company Secretary |
| Tan Li | Executive Director, Deputy General Manager |
| Yu Shan | Executive Director, General Manager |
Board
| Director | Role |
|---|---|
| Li Li | President and Chairman |
| Fengqi Qian | Secretary to the Board, Joint Company Secretary |
| Tan Li | Executive Director, Deputy General Manager |
| Yu Shan | Executive Director, General Manager |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 | +2.6% |
| Q2 2026 | Aug 31, 2026 | −3.5% |
| Q1 2026 | Apr 30, 2026 | |
| Q4 2025 | Mar 30, 2026 | +2.0% |
| Q3 2025 | Oct 31, 2025 | +4.7% |
| Q2 2025 | Sep 1, 2025 | 0.0% |
| Q1 2025 | Apr 25, 2025 | −2.7% |
| Q3 2024 | Oct 30, 2024 · Before open | −0.7% |
| Q2 2024 | Sep 2, 2024 | +0.7% |
| Q1 2024 | Apr 29, 2024 · Before open | +2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Jan 10, 2024 · After close | +1.0% |
| Q3 2023 | Oct 30, 2023 · Before open | +2.0% |
| Q2 2023 | Aug 30, 2023 · After close | +1.1% |
| Q1 2023 | Apr 28, 2023 · Before open | +0.1% |
| Q4 2022 | Mar 29, 2023 · After close | −0.1% |
| Q3 2022 | Oct 28, 2022 · After close | −6.0% |
| Q2 2022 | Aug 29, 2022 · Before open | +5.4% |
| Q1 2022 | Apr 29, 2022 · After close | |
| Q4 2021 | Mar 30, 2022 · Before open | +2.0% |
| Quarter to Sep 30, 2021 | Oct 27, 2021 · Before open | −1.9% |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.48B | 5.26B | 5.43B | 7.16B | 6.37B | 5.33B | 4.62B | 4.81B | 2.84B | 2.26B |
| Cost of revenue | 3.74B | 3.52B | 4.49B | 4.86B | 4.37B | 3.30B | 2.95B | 2.93B | 1.98B | 1.56B |
| Gross profit | 1.74B | 1.74B | 940.9M | 2.30B | 2.00B | 2.03B | 1.68B | 1.88B | 862.9M | 697.5M |
| Research and development | 226.2M | 212.0M | 182.4M | 252.1M | 221.1M | 160.0M | 148.7M | 186.5M | 93.5M | 62.0M |
| Selling, general and administrative | 478.2M | 638.5M | 674.5M | 457.2M | 420.2M | 412.7M | 352.9M | 295.1M | 382.3M | 389.6M |
| Operating income | 636.0M | 507.1M | -434.2M | 828.6M | 227.5M | 1.33B | 1.31B | 692.5M | 92.2M | 435.6M |
| Depreciation and amortization | 372.9M | 331.1M | 373.6M | 307.7M | 302.7M | 304.0M | 255.6M | 217.0M | 155.2M | 161.8M |
| EBITDA | 1.01B | 838.2M | -60.6M | 1.14B | 530.2M | 1.63B | 1.57B | 909.5M | 247.4M | 597.4M |
| Interest expense | 71.4M | 153.5M | 238.7M | 257.2M | 201.6M | 273.6M | 278.3M | 227.5M | 184.5M | 106.7M |
| Income before tax | 402.2M | 726.2M | -928.3M | 829.9M | 222.3M | 1.33B | 1.31B | 702.2M | 104.2M | 474.9M |
| Income tax | 101.3M | -126.2M | 114.8M | -11.1M | 306.2M | 271.4M | 134.0M | -94.8M | 88.8M | |
| Net income | 349.5M | 646.7M | -783.3M | 727.4M | 240.8M | 1.02B | 1.06B | 591.5M | 196.7M | 396.9M |
| Earnings per share, basic | 0.24 | 0.44 | -0.53 | 0.50 | 0.16 | 0.76 | 0.85 | 0.47 | 0.16 | 0.32 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 1.35B | 1.69B | 1.85B | 2.14B | 2.94B | 2.71B | 1.28B | 2.12B | 3.50B | 4.55B |
| Short-term investments | 1.48B | 868.4M | 414.2M | 1.31B | 981.2M | 828.2M | 112.6M | 79.2M | 288.4M | 13.4M |
| Receivables | 1.37B | 1.28B | 1.26B | 1.63B | 1.54B | 1.88B | 1.32B | 1.09B | 1.03B | 719.4M |
| Inventory | 4.45B | 5.39B | 6.65B | 6.84B | 4.71B | 3.17B | 2.37B | 1.53B | 857.3M | 584.8M |
| Current assets | 9.15B | 9.62B | 10.6B | 12.4B | 10.8B | 9.13B | 6.00B | 5.60B | 6.13B | 6.70B |
| Property, plant and equipment | 2.54B | 2.57B | 2.58B | 2.44B | 1.88B | 1.22B | ||||
| Goodwill | 2.30B | 2.36B | 2.32B | 2.35B | 2.15B | 2.20B | 2.35B | 2.32B | 2.21B | 2.34B |
| Total assets | 16.6B | 17.3B | 19.2B | 20.8B | 19.1B | 19.0B | 15.2B | 13.7B | 13.2B | 12.9B |
| Accounts payable | 257.1M | 299.7M | 302.2M | 427.4M | 385.8M | 239.2M | 228.7M | 205.3M | 164.3M | 70.9M |
| Current liabilities | 3.95B | 3.70B | 4.99B | 5.58B | 4.79B | 3.61B | 4.97B | 4.50B | 3.25B | 2.07B |
| Long-term debt | 298.1M | 1.08B | 1.81B | 2.30B | 2.25B | 3.09B | 2.36B | 2.46B | 1.83B | 2.10B |
| Total debt | 2.98B | 5.56B | 6.46B | 5.65B | 5.65B | 6.30B | 4.92B | 4.71B | 3.89B | |
| Total liabilities | 4.55B | 5.14B | 7.22B | 8.41B | 7.58B | 7.34B | 7.77B | 7.41B | 5.50B | 4.83B |
| Shareholders' equity | 12.0B | 12.1B | 11.9B | 12.3B | 11.4B | 11.6B | 7.35B | 6.07B | 7.58B | 7.97B |
| Shares outstanding | 1.47B | 1.47B | 1.48B | 1.47B | 1.47B | 1.35B | 1.25B | 1.25B | 1.25B | 1.25B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1.71B | 2.19B | 398.2M | -756.6M | -6.63M | 37.3M | -227.6M | 667.9M | -407.1M | 346.1M |
| Capital spending | -121.1M | -202.8M | -444.9M | -222.4M | -193.9M | -212.5M | -362.1M | -535.0M | -576.1M | -359.5M |
| Free cash flow | 1.59B | 1.99B | -46.7M | -979.0M | -200.5M | -175.2M | -589.7M | 132.9M | -983.2M | -13.5M |
| Cash from investing | -415.0M | 1.22B | 249.8M | 719.9M | -2.17B | 1.70M | -544.3M | -1.21B | -273.0M | |
| Cash from financing | -2.14B | -1.20B | 329.6M | -501.1M | 2.51B | -234.3M | -1.62B | 564.5M | 274.2M | |
| Dividends paid | -430.8M | -159.9M | -425.9M | -51.4M | -220.1M | -224.5M | -342.5M | -255.1M | -444.6M | -541.4M |
| Share buybacks | -473.0M | |||||||||
| Change in cash | -233.3M | -343.8M | 445.9M | -159.9M | 149.4M | 253.7M | -449.6M | -1.47B | -1.06B | 360.3M |
Cap table
Built by 6ix from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class A’s releases
- Common shares
- 1,247,201,704
- Fully diluted
- 1,247,201,704
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,247,201,704 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,247,201,704 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Fengqi Qian | Secretary to the Board, Joint Company Secretary · Since at least Nov 6, 2026 |
| Juan Chen | Chief Financial Officer · Since at least Nov 6, 2026 |
| Li Li | President and Chairman · Since at least Nov 6, 2026 |
| Tan Li | Executive Director, Deputy General Manager · Since at least Nov 6, 2026 |
| Yu Shan | Executive Director, General Manager · Since at least Nov 6, 2026 |
Log in to ask 6ix AI your own questions about Shenzhen Hepalink Pharmaceutical Group Co., Ltd.